0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > DLL4

DLL4

Brief Information

Name:Delta-like protein 4
Target Synonym:Delta-Like Protein 4,Notch Ligand Delta-2,DLL4,Delta4,Delta-Like 4 (Drosophila),Delta-Like 4 Homolog (Drosophila),AOS6,Hdelta2,Notch Ligand DLL4,Delta Like Canonical Notch Ligand 4,Delta 4,Delta Ligand 4,Delta-Like 4 Protein,Drosophila Delta Homolog 4,Delta-Like 4 Homolog
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

DL4-H82E6-Cell-based assay
 DLL4 CELL

Biotinylated Human DLL4, His,Avitag, premium grade (Cat. No. DL4-H82E6) enhances Human BMP-2 Protein, premium grade (Cat. No. BM2-H4117) induced alkaline phosphatase activity in ATDC5 cells. The EC50 for this effect is 1.579 μg/mL (Routinely tested).

DL4-H5255-SPR
 DLL4 SPR

Human DLL4 Protein, Fc Tag, premium grade (Cat. No. DL4-H5255) captured on Protein A Chip can bind Human NOTCH1 Protein, His Tag, premium grade (Cat. No. NO1-H52H3) with an affinity constant between 1.00 nM - 150 nM as determined in a SPR assay (Biacore 8K) (QC tested).

GMP-DL4H28-SPR
 DLL4 SPR

GMP Human DLL4 Protein, Fc Tag (Cat. No. GMP-DL4H28) captured on Protein A Chip can bind Human NOTCH1 Protein, His Tag, premium grade (Cat. No. NO1-H52H3) with an affinity constant between 1.00 nM - 150 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Customer Reviews

Synonym Name

DLL4,Delta4

Background

Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TR-009 NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009; HD-B001A; HDB001A; TR-009 Phase 3 Clinical Abl Bio Inc Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms Details
Navicixizumab OMP-305B83 Phase 3 Clinical Oncomed Pharmaceuticals Inc Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms Details
Dilpacimab ABT-165; DVD-Ig ABT-165 Phase 1 Clinical Abbvie Inc Solid tumours; Neoplasms Details
TR-009 NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009; HD-B001A; HDB001A; TR-009 Phase 3 Clinical Abl Bio Inc Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms Details
Navicixizumab OMP-305B83 Phase 3 Clinical Oncomed Pharmaceuticals Inc Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms Details
Dilpacimab ABT-165; DVD-Ig ABT-165 Phase 1 Clinical Abbvie Inc Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message